Trial · NCT02607722
Adverse events448
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 448
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | IPF Patients Receiving Nintedanib | 2,036 | 5,734 | |
| other | Nausea | Gastrointestinal disorders | IPF Patients Receiving Nintedanib | 347 | 5,734 | |
| other | Hepatic function abnormal | Hepatobiliary disorders | IPF Patients Receiving Nintedanib | 829 | 5,734 | |
| other | Liver disorder | Hepatobiliary disorders | IPF Patients Receiving Nintedanib | 437 | 5,734 | |
| other | Decreased appetite | Metabolism and nutrition disorders | IPF Patients Receiving Nintedanib | 579 | 5,734 | |
| serious | Acquired haemophilia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 1 | 5,734 | |
| serious | Agranulocytosis | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 1 | 5,734 | |
| serious | Anaemia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 5 | 5,734 | |
| serious | Autoimmune haemolytic anaemia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 1 | 5,734 | |
| serious | Blood loss anaemia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 1 | 5,734 | |
| serious | Disseminated intravascular coagulation | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 7 | 5,734 | |
| serious | Febrile neutropenia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 7 | 5,734 | |
| serious | Haemolytic anaemia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 1 | 5,734 | |
| serious | Immune thrombocytopenia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 2 | 5,734 | |
| serious | Myelosuppression | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 1 | 5,734 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | IPF Patients Receiving Nintedanib | 4 | 5,734 | |
| serious | Acute myocardial infarction | Cardiac disorders | IPF Patients Receiving Nintedanib | 6 | 5,734 | |
| serious | Angina pectoris | Cardiac disorders | IPF Patients Receiving Nintedanib | 2 | 5,734 | |
| serious | Angina unstable | Cardiac disorders | IPF Patients Receiving Nintedanib | 1 | 5,734 | |
| serious | Aortic valve incompetence | Cardiac disorders | IPF Patients Receiving Nintedanib | 2 | 5,734 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02607722/events